Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Conmed (CNMD) over the last 16 years, with Q4 2025 value amounting to $225000.0.

  • Conmed's Other Working Capital Changes fell 9377.94% to $225000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $13.2 million, marking a year-over-year decrease of 539.9%. This contributed to the annual value of $13.2 million for FY2025, which is 539.9% down from last year.
  • Conmed's Other Working Capital Changes amounted to $225000.0 in Q4 2025, which was down 9377.94% from $3.1 million recorded in Q3 2025.
  • In the past 5 years, Conmed's Other Working Capital Changes registered a high of $11.4 million during Q1 2023, and its lowest value of -$133000.0 during Q4 2023.
  • Moreover, its 5-year median value for Other Working Capital Changes was $4.9 million (2022), whereas its average is $4.5 million.
  • Over the last 5 years, Conmed's Other Working Capital Changes had its largest YoY gain of 302763.98% in 2023, and its largest YoY loss of 10220.75% in 2023.
  • Conmed's Other Working Capital Changes (Quarter) stood at $8.1 million in 2021, then fell by 25.53% to $6.0 million in 2022, then tumbled by 102.21% to -$133000.0 in 2023, then surged by 2819.55% to $3.6 million in 2024, then tumbled by 93.78% to $225000.0 in 2025.
  • Its Other Working Capital Changes stands at $225000.0 for Q4 2025, versus $3.1 million for Q3 2025 and $4.5 million for Q2 2025.